Sibutramine

Drug Profile

Sibutramine

Alternative Names: Aoquqing; BTS 54524; Ectiva; KES 524; Meridia; Reductase; Reductil; Reduxade; Sibutral

Latest Information Update: 24 Jan 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Abbott GmbH & Co. KG; AstraZeneca; Eisai Co Ltd; Il Sung; Nanjing Chang'ao Pharmaceutical
  • Class Anorectics; Cyclobutanes; Obesity therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Obesity
  • Discontinued Major depressive disorder

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 28 Oct 2010 Discontinued - Preregistration for Obesity in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top